Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Roquefort Investments PLC ( (GB:ROQ) ) has issued an update.
Roquefort Therapeutics PLC announced an amendment to its exclusive license agreement with Coiled Therapeutics, Inc. and A2A Pharmaceuticals, Inc. for the AO-252 drug, extending the long stop date to March 16, 2026. The amendment reflects significant progress in the Phase I clinical trial, which has expanded to include all solid tumors and prioritized prostate cancer. This strategic focus is supported by promising pre-clinical data and positive feedback from potential partners, highlighting the commercial interest in novel oral therapies for prostate cancer. The extension allows more time for data readouts and involves changes to the commercial terms, including an increase in consideration shares, underscoring the potential value of the AO-252 program.
More about Roquefort Investments PLC
Roquefort Therapeutics PLC is a biotech company listed on the Main Market, focusing on developing innovative therapies for cancer treatment. The company is involved in clinical trials and has a market focus on oral targeted therapies for solid tumors, particularly prostate cancer.
Average Trading Volume: 2,513,152
Technical Sentiment Signal: Sell
Current Market Cap: £2.05M
See more insights into ROQ stock on TipRanks’ Stock Analysis page.